Comprehensive Discussions With PCPs Increase Cancer Screening

Share this content:
Comprehensive Discussion With Docs Ups Cancer Screening
Comprehensive Discussion With Docs Ups Cancer Screening

(HealthDay News) -- Having more comprehensive discussions about colorectal cancer (CRC) screening with primary care providers (PCPs) is associated with increased odds of screening, according to a study published in the April issue of the American Journal of Managed Care.

David M. Mosen, Ph.D., M.P.H., from Kaiser Permanente Northwest in Portland, Ore., and colleagues examined the correlation between the comprehensiveness of CRC screening discussion by PCPs and the completion of screening in a observational study involving 883 participants overdue for CRC screening. Of the 249 participants who completed screening, 84 percent were surveyed about their PCPs' discussion of CRC screening and patient beliefs pertaining to screening.

The researchers found that the average score for comprehensiveness of CRC discussion was 0.4 (range 0 to 1) and the average score for perceived benefits of screening was 4.0 (range 1 to 5). Almost all screeners completed the fecal immunochemical test (95.2 percent). The odds of screening were significantly increased with more comprehensive discussion of CRC screening (odds ratio [OR], 1.51). Increased screening was also associated with higher perceived benefits (OR, 1.46) and with one or more PCP visits (OR, 5.82).

"We found that patients' self-report of more comprehensive discussion of CRC screening by PCPs and a greater perceived level of benefit were independently associated with receipt of CRC screening," the authors write. "This suggests that CRC screening efforts may be usefully directed toward increasing the intensity of screening discussion by PCPs and other care providers."

Full Text

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs